Alpha-emitter anticancer agents

Algeta developed Xofigo® (radium-223 dichloride), a first-in-class, targeted alpha-pharmaceutical that was approved by the US FDA and European EMA for treatment of patients with symptomatic bone metastases secondary to castration-resistant prostate cancer.

CEO  Andrew Kay

Advent Contact  Shahzad Malik

Advent invested in the Series A in 2005. Algeta listed on the Oslo Stock exchange in March 2007 and was acquired by Bayer in 2014 for $2.9B.
Exited Investments
20 January 2014 in Algeta, Press Release

Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta

Press Release.   Oslo, Norway, 20 January, 2014 - Algeta ASA ("Algeta"; OSE: ALGETA) today announced that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the…
Read More
19 December 2013 in Algeta, Press Release

The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta

Press Release.   Not intended for US media Offer at NOK 362 per Algeta share, in cash, valuing the total share capital of Algeta at approximately NOK 17.6 billion (USD…
Read More
15 May 2013 in Algeta, Press Release

Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA

Press Release.   New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases Xofigo shown in a pivotal phase III trial to significantly improve overall survival Algeta to host…
Read More
14 December 2012 in Algeta, Press Release

Algeta’s partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride

Press Release.   Oslo, Norway, 14 December 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer has submitted a New Drug Application (NDA) to the US Food and Drug Administration…
Read More